![]()
|
|
||||||||
, and Leukemia Inhibitory Factor
Utilize Insulin Receptor Substrate-2 in Intracellular Signaling*
(Received for publication, March 19, 1996, and in revised form, August 16, 1996)
§,
,


From the
Department of Physiology, The University of
Michigan Medical School, Ann Arbor, Michigan 48109-0622, the ** Joslin
Diabetes Center and Department of Medicine, Harvard Medical School,
Boston, Massachusetts 02215, the ¶ Center for BioTechnology,
Karolinska Institute, Novum, 141 57 Huddinge, Sweden, and the
Hagedorn Research Laboratory, Niels Steensensvej 6, DK-2820 Gentofte, Denmark
In this report, we demonstrate that insulin
receptor substrate-2 (IRS-2) is tyrosyl-phosphorylated following
stimulation of 3T3-F442A fibroblasts with growth hormone (GH), leukemia
inhibitory factor and interferon-
. In response to GH and leukemia
inhibitory factor, IRS-2 is immediately phosphorylated, with maximal
phosphorylation detected at 15 min; the signal is substantially
diminished by 60 min. In response to interferon-
, tyrosine
phosphorylation of IRS-2 was prolonged, with substantial signal still
detected at 60 min. Characterization of the mechanism of signaling
utilized by GH indicated that tyrosine residues in GH receptor are not necessary for tyrosyl phosphorylation of IRS-2; however, the regions of
GH receptor necessary for IRS-2 tyrosyl phosphorylation are the same as
those required for JAK2 association and tyrosyl phosphorylation. The
role of IRS-2 as a signaling molecule for GH is further demonstrated by
the finding that GH stimulates association of IRS-2 with the 85-kDa
regulatory subunit of phosphatidylinositol 3
-kinase and with the
protein-tyrosine phosphatase SHP2. These results are consistent with
the possibility that IRS-2 is a downstream signaling partner of
multiple members of the cytokine family of receptors that activate JAK
kinases.
IRS-11 is a major cytoplasmic
substrate of insulin receptor (1) and several cytokine receptors that
are coupled to Janus kinases. The latter group includes growth hormone
(GH) receptor, which mediates tyrosine phosphorylation of IRS-1 in
3T3-F442A fibroblasts, CHO cells expressing GH receptor (GHR), and
primary cultures of rat adipocytes (2, 3, 4). In addition, the 85-kDa
regulatory subunit of phosphatidylinositol (PI) 3
-kinase associates
with IRS-1 and becomes activated in response to GH. Tyrosyl
phosphorylation of IRS-1 in response to GH suggests that GH shares some
pathways utilized by insulin.
Recently, a second IRS protein was identified, which was designated
IRS-2 (5). It migrates with a Mr slightly larger
than IRS-1. IRS-2 has substantial structural similarity to IRS-1 with multiple potential tyrosyl phosphorylation sites, 13 of which are
identical or show substantial identity to sites present in IRS-1.
Conserved sites include those previously seen to bind Grb2, the
protein-tyrosine phosphatase SHP2, and the 85-kDa regulatory subunit of
PI 3
-kinase. IRS-2 is the dominant tyrosyl-phosphorylated protein
interacting with PI 3
-kinase and Grb2 in IRS-1-deficient mice (6, 7).
The ability of IRS-2 to substitute for IRS-1 is further suggested by
the finding that both IRS-1 and IRS-2 mediate insulin and
IL-4-stimulated mitogenesis in 32D cells (5).
In this report, we demonstrate that IRS-2 is rapidly phosphorylated on
tyrosines in response to GH, LIF, and IFN
. GH-dependent tyrosyl phosphorylation of IRS-2 requires two regions within the cytoplasmic domain of GHR; the same regions are required for JAK2 association and tyrosyl phosphorylation (3, 8, 9). GH is also shown to
promote association of IRS-2 with both PI 3
-kinase and SHP2. This and
recent reports of IRS-2 tyrosyl phosphorylation in response to IL-2,
IL-4, and IL-7 (cytokines that activate JAK1 and JAK3; Ref. 10), and
IFN
(a cytokine that activates JAK1 and Tyk2; Ref. 11) suggest that
signaling through IRS-2 may be a common element in signaling for many
members of the cytokine family of receptors that activate JAK tyrosine
kinases.
Recombinant 22,000-dalton hGH and porcine insulin
were a gift of Lilly. Human recombinant IGF-1 was from Calbiochem.
Murine recombinant LIF was from R & D Systems. Murine recombinant
IFN
and chicken egg ovalbumin were from Sigma.
Recombinant protein A-agarose was from Repligen. Protein assay kit
(BCA) was from Pierce. Aprotinin, leupeptin, and Triton X-100 were
purchased from Boehringer Mannheim. Bovine serum albumin (CRG-7) was
from Intergen. Prestained molecular weight standards were from Life Technologies, Inc. Nitrocellulose paper was from Schleicher & Schuell.
The enhanced chemiluminescence (ECL) detection system was from
Amersham. X-ray film was from DuPont.
Anti-phosphotyrosine binding antibody (
Tyr(P))
(4G10), and antiserum to the 85-kDa subunit of PI 3
-kinase (for
immunoprecipitation 05-212, for blotting 06-195) (
p85) and SHP2
(06-118) (
SHP2) were purchased from Upstate Biotechnology, Inc.
Antibody to IRS-1 (
IRS-1) was prepared against recombinant IRS-1
(12). Antibody to IRS-2 (
IRS-2) was prepared in rabbits to a
glutathione S-transferase fusion protein containing amino
acids 619-746 of murine IRS-2 (5). Antibody to JAK2 (
JAK2) was
prepared against a synthetic peptide corresponding to amino acids
758-776 of murine JAK2 (13).
CHO cells
expressing full-length rat GHR or GHR mutated to replace lysine codons
455, 381, 319, or 295 with termination codons; or to delete the codons
for amino acids 297-311; or to replace tyrosine codons 333 and 338 with codons for phenylalanine have been described previously (3). Amino
acids in GHR are numbered according to Ref. 14. The binding affinity of
each cell line for hGH was similar (15,
16).2 The relative 125I-GH
binding by CHO cell lines expressing various GHRs was GHR-1-638 (wild
type), 100%; GHR1-454, 130%; GHR1-380, 70%; GHR1-318, 60%; GHR1-294, 280%; and GHR
P, 60%; GHR1-454Y(333, 338)F, 90%. The stock of 3T3-F442A cells was a kind gift of H. Green (Harvard University, Boston, MA). Conditions used to culture CHO and 3T3-F442A cells have been described previously (3).
Confluent cells were
incubated in serum-free medium overnight (16-20 h) as described
previously (17). Cells were incubated at 37 °C with hGH, cytokine,
or growth factor at the indicated concentrations for various time
intervals and then rinsed three times with ice-cold PBSV (10 mM sodium phosphate, pH 7.4, 150 mM NaCl, 1 mM Na3VO4). Cells were solubilized
in lysis buffer (50 mM Tris, pH 7.5, 0.1% Triton X-100,
150 mM NaCl, 2 mM EGTA, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin), and centrifuged
at 14,000 × g for 10 min. The supernatants were
incubated on ice for 3 h with the indicated antibody. Immune
complexes were collected on protein A-agarose for 1 h at 8 °C;
washed three times with 50 mM Tris, pH 7.5, 0.1% Triton
X-100, 150 mM NaCl, 2 mM EGTA, 1 mM
Na3VO4; and boiled for 5 min in a mixture
(80:20) of lysis buffer and 250 mM Tris, pH 6.8, 5% SDS,
10%
-mercaptoethanol, 40% glycerol. Immunoprecipitated proteins
were resolved by SDS-polyacrylamide gel electrophoresis (30:0.5,
acrylamide:bisacrylamide) on 5-12% gradient polyacrylamide gels (when
visualizing IRS-2 and PI 3
-kinase) or 8% gels (for SHP2). For
experiments using CHO cells, the protein content of the cell
supernatant was determined and used to normalize the amount of sample
added to each lane. When visualizing IRS-2, proteins were transferred
to nitrocellulose at 100 V at 4 °C for 2 h in 25 mM
Tris, 190 mM glycine, 20% methanol, 0.02% SDS. When
visualizing PI 3
-kinase and SHP2, the SDS was omitted and proteins
transferred for 1 h. Blots were incubated with the appropriate
antibody and visualized by ECL detection as described previously (17).
To reprobe a blot with a second antibody, the blot was rinsed,
incubated (in 2% SDS, 60 mM Tris, pH 6.7, 100 mM
-mercaptoethanol) at 50 °C for 30 min, reprobed
without adding additional primary antibody to verify that all primary
antibody had been removed, and then reprobed using the second
antibody.
For quantification, autoradiographs were scanned using an Agfa ArcusII
scanner and Fotolook SA software (Mortsel, Belgium). The resulting
image was analyzed using Molecular Analyst image analysis software from
Bio-Rad. Ligand-dependent tyrosyl phosphorylation of IRS-2,
and association of the 85-kDa subunit of PI 3
kinase or SHP2 with
IRS-2 is compared to treatment with vehicle. Means and standard errors
(S.E.) of independent experiments are reported. Tyrosyl phosphorylation
of IRS-2 in CHO cells expressing various GHR mutants is compared to
stimulation observed with vehicle alone in cells expressing GHR1-638.
One-tailed paired Student's t tests were used to assess
statistical significance.
Homology searches were performed using the EditSeq program from DNAstar, Inc.
, and LIF to Stimulate IRS-2 Tyrosyl
Phosphorylation
Signaling utilizing IRS-2 appears to be dependent
upon its tyrosyl phosphorylation (6, 7). To determine if IRS-2 is tyrosyl-phosphorylated in response to GH, 3T3-F442A fibroblasts were
incubated for 15 min with different concentrations of GH. Cellular
proteins were solubilized, immunoprecipitated with
IRS-2, and
immunoblotted with
Tyr(P). Concentrations of GH as low as 5 ng/ml
(0.23 nM) induced tyrosyl phosphorylation of a protein with
a Mr (180,000-190,000) appropriate for IRS-2
(Fig. 1, lanes B-F). At 500 ng/ml GH,
tyrosyl phosphorylation of this protein is 4.2 times (S.E. = 0.5, n = 5) that seen in vehicle-treated cells. Consistent
with this phosphoprotein being IRS-2, it co-migrates with a protein in
the immunoprecipitate that is recognized by
IRS-2 in immunoblots
(Fig. 1, lane A), co-migrates with IRS-2 phosphorylated in
response to IGF-1 and insulin (Fig. 1, lanes G and
H), and migrates as a slightly larger protein than IRS-1 (Fig. 1, lane I).
IRS-2
(1:250 dilution) (lanes A-H),
IRS-1 (1:250 dilution) (lane I), or
JAK2 (1:200 dilution) (lane J).
Immunoprecipitated proteins were immunoblotted with
Tyr(P) (1:7500
dilution) (lanes B-J). For lane A the blot was
stripped and reprobed with
IRS-2 (1:2000 dilution). The molecular
weight (×10
3) of protein standards and the migration of
IRS-2, IRS-1, and JAK2 are indicated.
To examine whether other cytokines that activate JAK2 stimulate tyrosyl
phosphorylation of IRS-2, 3T3-F442A fibroblasts were treated with GH,
IFN
, or LIF at concentrations determined, in experiments not shown,
to be sufficient to yield maximal tyrosyl phosphorylation of JAK2 at 15 min. Ligand-dependent tyrosyl phosphorylation of IRS-2 is
detected in response to IFN
and LIF, as well as to GH (Fig.
2A). However, tyrosyl phosphorylation of
IRS-2 following treatment with IFN
or LIF is substantially less than
that following stimulation with GH. Differences in the time course for
IRS-2 phosphorylation by the different ligands are also detected. In response to GH and LIF, maximal signal is detected at 15 min. For LIF
the signal is 2.5 times (S.E. = 0.6, n = 3) and for GH 4.2 times (S.E. = 0.5, n = 5) the signal detected with
vehicle alone. The signal is diminished by 60 min (Fig. 2, B
and C). In contrast, with IFN-
onset of IRS-2 tyrosyl
phosphorylation is slower and the signal is more prolonged, at 15 min
the signal is 1.9 times (S.E. = 0.4, n = 3), and at 60 min 2.2 times (range = 0.7, n = 2) the signal with
vehicle alone (Fig. 2D). For comparison, in response to
insulin, by 1 min tyrosyl phosphorylation of IRS-2 is 15 times (S.E. = 4.6, n = 3) the signal with vehicle alone, and present
at approximately 50% of this level from 5 to 60 min (Fig.
2E).
, and insulin
induced tyrosyl phosphorylation of IRS-2. Panel A, 3T3-F442A
fibroblasts were incubated at 37 °C for 15 min with vehicle
(C) (lanes A and E), 10 ng/ml (0.7 nM) IFN
(lanes B and F), 25 ng/ml
(1.3 nM) LIF (lanes C and G), or 500 ng/ml (23 nM) GH (lanes D and H). Cell lysates were immunoprecipitated with
IRS-2 (1:250 dilution) (lanes A-D) or
JAK2 (1:200 dilution) (lanes
E-H). Immunoprecipitated proteins were immunoblotted with
Tyr(P) (1:7500 dilution). Panels B-E, 3T3-F442A
fibroblasts were incubated with: B, 500 ng/ml (23 nM) hGH; C, 10 ng/ml (0.7 nM)
IFN
; D, 25 ng/ml (1.3 nM) LIF; E,
28 ng/ml (5 nM) insulin at 37 °C for the indicated
times. Cell lysates were immunoprecipitated with
IRS-2 (1:250
dilution) (lanes A-F) or
JAK2 (1:200 dilution)
(lanes G-L). Immunoprecipitated proteins were immunoblotted
with
Tyr(P) (1:7500 dilution). The molecular weight
(×10
3) of protein standards and the migrations of IRS-2,
JAK2, and insulin receptor (IR) are indicated. The
concentrations of GH, IFN
, and LIF used were sufficient to yield
maximal JAK2 tyrosyl phosphorylation at 15 min (data not shown).
To determine if differences in the magnitude of IRS-2 tyrosyl
phosphorylation correlate with tyrosyl phosphorylation of JAK2 induced
by GH, LIF, and IFN
, ligand-dependent tyrosyl
phosphorylation of JAK2 was monitored by immunoprecipitating with
JAK2 and immunoblotting with
Tyr(P) (Fig. 2A,
lanes E-H; see also lanes G-L of panels B-D). The relative magnitude and time course of IRS-2 tyrosyl phosphorylation reflected the JAK2 tyrosyl phosphorylation induced by
each ligand. This correlation suggests that JAK2 activation may be
necessary for IRS-2 tyrosyl phosphorylation. Similarly, following
insulin stimulation, tyrosyl phosphorylation of IRS-2 correlates with
tyrosyl phosphorylation of insulin receptor (Fig. 2E).
Whether ligand-dependent differences in the extent of
tyrosyl phosphorylation of IRS-2 and JAK2 result from intrinsic
differences in the responses elicited by each ligand or reflect
differences in the number of GH, LIF, and IFN
receptors expressed in
3T3-F442A fibroblasts is not known. However, consistent with the
results in 3T3-F442A fibroblasts, in IM-9 lymphocytes, rapid transient stimulation of JAK2 tyrosyl phosphorylation is detected in response to
GH, while prolonged JAK2 tyrosyl phosphorylation (essentially equivalent at 10 and 60 min) is observed in response to IFN
(18). Thus, substantial temporal differences in activation and deactivation of JAK2 and IRS-2 in response to GH, LIF, and INF
appear to be present.
Following stimulation by GH, LIF, and insulin, IRS-2 migrates as a
broader band at the later time points (Fig. 2, B,
C, and E). This effect is not observed with
IFN
(Fig. 2D). Broadening of the IRS-2 band was also
observed to be dependent upon the concentration of GH, with broadening
observed only at higher concentrations (Fig. 1). Since a decrease in
the mobility of a protein is often associated with increased protein
phosphorylation, ligand-dependent differences in IRS-2
mobility suggest that individual phosphorylation sites (serine,
threonine, or tyrosine) in IRS-2 may be phosphorylated to varying
degrees, in response to the different ligands.
In addition to IRS-2, tyrosyl-phosphorylated proteins with
Mr = 120,000-130,000 are also detected in
IRS-2 immunoprecipitates from LIF and GH-treated cells (Fig. 1,
lanes E and F; Fig. 2, A-C,
lanes C and D). The lower portion of the
120-130-kDa band is also detected following IGF-1 treatment (Fig. 1,
lane H). Coprecipitation of a tyrosyl-phosphorylated protein
with this Mr has previously been observed in rat
FAO hepatoma cells following insulin treatment (5). This protein could
be Gab1, a protein with homology to IRS-1, especially in the pleckstrin
homology domain. Gab1 was recently shown to undergo
insulin-dependent tyrosyl phosphorylation in A431 cells and
to bind Grb2, phospholipase C
, PI 3
-kinase, and SHP2 (19).
Following GH (but not IGF-1 or insulin) stimulation, the upper portion
of the 120-130-kDa band contains a distinct protein which co-migrates
with JAK2; however, insufficient protein is co-precipitated to permit
identification by immunoblotting with
JAK2. The inability to detect
this protein following treatment with LIF and IFN
is thought to be
due to the smaller amount of IRS-2 that is phosphorylated. The ability
of JAK2 to associate with IRS-2 in response to GH was also tested by
immunoprecipitating with
JAK2. Only protein that comigrates with
IRS-1 is detected; no IRS-2 is detected (Fig. 1, lane J).
These results suggest that IRS-2 may be present in a complex with JAK2.
However, it appears that less IRS-2 than IRS-1 is present and/or the
affinity of JAK2 for IRS-2 is less than for IRS-1.
-Kinase with
IRS-2
IRS-1, IRS-2, and JAK2 each contain the YXXM
motif preferentially recognized by the Src homology 2 domains of the
85-kDa regulatory subunit of PI 3
-kinase (p85) (5, 13, 20).
Furthermore, p85 binds to IRS-2 and is activated following insulin
stimulation (6, 7). To determine if GH promotes association of p85 with IRS-2 or with JAK2, solubilized 3T3-F442A fibroblasts were
immunoprecipitated with
IRS-2 or
JAK2 and immunoblotted with
p85. Following GH treatment, the amount of 85-kDa subunit of PI
3
-kinase that co-precipitates with IRS-2 is 2.1 times (S.E. = 0.2, n = 4) the level detected following treatment with
vehicle alone (Fig. 3A, lanes A
and B). This protein is identified by
p85 in immunoblots
(Fig. 3A, lane D). In contrast, p85 does not
appear to associate directly with JAK2, since p85 was not detected in
JAK2 immunoprecipitates of GH-treated cells (Fig. 3A,
lanes E and F). No p85 is detected with nonimmune
serum (Fig. 3A, lane C). When proteins from
GH-treated cells were immunoprecipitated with
p85 and immunoblotted
with
Tyr(P), tyrosyl-phosphorylated proteins that co-migrate with IRS-2, IRS-1, GHR, and JAK2 are detected (Fig. 3B). Thus, it
appears that PI 3
-kinase is present in a multiprotein complex
containing GHR, JAK2, IRS-1, and IRS-2; however, PI 3
-kinase appears
to associate directly with IRS-2. This is consistent with the previous finding that PI 3
-kinase directly associates with IRS-1 (3).
-kinase with IRS-2. Panel
A, 3T3-F442A fibroblasts were incubated at 37 °C for 15 min in
the absence (
) (lanes A and E) or presence (+)
(lanes B-D and F) of 500 ng/ml hGH. Cell lysates
were immunoprecipitated with
IRS-2 (1:250 dilution) (lanes A and B), nonimmune serum (1:200 dilution) (lane
C),
p85 (1:200 dilution) (lane D), or
JAK2 (1:200
dilution) (lanes E and F). Imunoprecipitated
proteins were immunoblotted with
p85 (1:2000 dilution). Panel
B, 3T3-F442A fibroblasts were incubated at 37 °C for 15 min in
the absence (
) (lanes A, C, and E)
or presence (+) (lanes B, D, and F) of
500 ng/ml hGH. Cell lysates were immunoprecipitated with
IRS-1
(1:250 dilution) (lanes A and B),
IRS-2 (1:250
dilution) (lanes C-D), or
p85 (1:200 dilution) (lanes E
and F). Imunoprecipitated proteins were immunoblotted with
Tyr(P) (1:7500 dilution). The molecular weight (×10
3)
of protein standards and the migration of p85, IRS-2, IRS-1, JAK2, and
GHR are indicated.
Ability of GH to Induce Association of SHP2 with IRS-2
Binding sites for SHP2 present in IRS-1 are conserved in
IRS-2 (5). To determine if GH can induce association of SHP2 with IRS-2, solubilized 3T3-F442A fibroblasts were immunoprecipitated with
IRS-2 and immunoblotted with
SHP2. Following GH treatment, the
amount of SHP2 that specifically co-precipitates with IRS-2 is 2.9 times (S.E. = 0.1, n = 3) the level with vehicle alone (Fig. 4, lanes A and B). Thus, GH
stimulates association of SHP2 with IRS-2 in these cells.
) (lanes A and D) for 15 min, 500 ng/ml (23 nM) hGH (GH) (lanes B,
E, and G) for 15 min, or 28 ng/ml (5 nM) insulin for 5 min (lanes C and F). Cell lysates were immunoprecipitated with
IRS-2
(1:250 dilution) (lanes A-C), nonimmune serum (1:200
dilution) (lanes D-F), or
SHP2 (1:100 dilution)
(lane G). Immunoprecipitated proteins were immunoblotted
with
SHP2 (1:1000 dilution). The molecular weight (×10
3) of protein standards and the migration of SHP2
are indicated.
Identification of the Region of GHR Necessary for IRS-2 Tyrosyl Phosphorylation
To begin to understand the molecular basis for
the interaction between IRS-2 and GHR, the ability of mutated GHR to
stimulate tyrosyl phosphorylation of IRS-2 was evaluated (mutants
summarized in Fig. 5). CHO cells expressing the
respective GHR mutants were solubilized, IRS-2 was immunoprecipitated
using
IRS-2 and immunoblotted with
Tyr(P). GHR1-638 (wild-type),
GHR1-454, and to a lesser extent GHR1-380 promote a
GH-dependent increase in IRS-2 tyrosyl phosphorylation
(Fig. 6, A and B, lanes
A-F). No GH-dependent tyrosyl phosphorylation of
IRS-2 is detected in cells expressing GHR1-318, GHR1-294, and GHR
P
(Fig. 6, A and B, lanes G-L). In GHR
P, amino acids 297-311 of GHR have been deleted, which removes the proline-rich box 1 motif that is conserved in many members of the
cytokine family of receptors (21). Thus, two regions in the cytoplasmic
domain of GHR appear to be required for GH-mediated tyrosyl
phosphorylation of IRS-2, one between amino acids 297 and 311 and
another between amino acids 318 and 380.
) or presence (+) of 500 ng/ml hGH at 37 °C for 15 min. Cell lysates were immunoprecipitated
with
IRS-2 (1:250 dilution) or
JAK2 (1:200 dilution) as
indicated. Immunoprecipitated proteins were immunoblotted with
Tyr(P) (1:7500 dilution). The molecular weight (×10
3)
of protein standards and the migration of IRS-2 and JAK2 are indicated.
Lanes A-L and M-P are from separate
experiments. Panel B, levels of tyrosyl phosphorylation of
IRS-2 in CHO cells expressing the indicated GHR were quantified and
normalized to vehicle-treated cells expressing GHR1-638. The data are
expressed as the mean ± range (n = 2) for
GHR1-638, GHR1-454, and GHR1-454Y(333,338)F; or as the mean ± S.E. (n = 3) for GHR1-380, GHR1-294, and GHR
P. For
each transfected GHR, one-tailed paired t tests were used to
assess whether vehicle and GH-treated values were statistically significant. Significant differences (p < 0.05) are
denoted with an asterisk (*).
The increase in basal IRS-2 tyrosyl phosphorylation in cells expressing GHR1-454 and GHR1-380 compared to GHR1-638 (Fig. 6, A and B, lanes C and E) was consistently detected. A similar effect was seen with IRS-1 (3). Increased basal JAK2 activity does not appear to be involved, since in these cell lines, JAK2 tyrosyl phosphorylation is not detected in the absence of GH (8). This raises the possibility that a binding site/regulatory region for a phosphatase may be present between amino acids 455 and 638 of GHR.
A tyrosine in the context of an NPXY motif in the receptors for insulin, IGF-1, and IL-4 is required for tyrosyl phosphorylation of IRS-1 in response to these ligands (22, 23, 24, 25). When phosphorylated, the NPXY motif of these receptors interacts with the phosphotyrosine-binding domain in IRS-1 (IH-2PTB). This domain is highly conserved between IRS-1 and IRS-2 (5). Thus, ligand-dependent tyrosyl phosphorylation of either the ligand receptor or an associated molecule is thought to be required for interaction with IRS-2. Between amino acids 295 and 380, the region of GHR required for GH-dependent IRS-2 tyrosyl phosphorylation, rat GHR contains tyrosines at amino acids 333 and 338. One or both of these tyrosines appear to be phosphorylated in response to GH (26). To determine if these tyrosines are required for IRS-2 tyrosyl phosphorylation, tyrosines 333 and 338 of GHR were mutated to phenylalanines in GHR1-454. The remaining two tyrosines in GHR1-454 do not appear to be tyrosyl-phosphorylated (26). When expressed in CHO cells, GHR1-454Y(333,338)F mediates GH-dependent tyrosyl phosphorylation of IRS-2 (Fig. 6, panel A, lanes O and P; and panel B, lanes M and N). Therefore, phosphorylation of tyrosines in GHR does not appear to be required for GH-dependent tyrosyl phosphorylation of IRS-2.
The proline-rich box 1 motif and the region between amino acids 318 and 380 in the cytoplasmic domain of GHR required for IRS-2 phosphorylation are also required for GH-dependent tyrosyl phosphorylation of JAK2 and JAK2 association with GHR (Fig. 6) (8, 9, 27). Thus, the function of GHR in mediating GH-dependent IRS-2 tyrosyl phosphorylation may be to transduce the signal that activates JAK2. Consistent with IRS-2 interacting with either tyrosyl-phosphorylated JAK2 or a molecule associated with tyrosyl-phosphorylated JAK2, the ability of each mutant GHR to mediate GH-dependent tyrosyl phosphorylation of IRS-2 correlates with the amount of JAK2 tyrosyl phosphorylation detected (Fig. 6A). Since GH-dependent tyrosyl phosphorylation of JAK2 reflects JAK2 kinase activity,3 this correlation further suggests that, either directly or indirectly, JAK2 kinase activity is required for IRS-2 phosphorylation.
Work presented in this paper using 3T3-F442A fibroblasts and CHO
cells expressing GHR provides strong evidence that IRS-2 is a component
of GH signaling. Thus both IRS family members identified to date, IRS-1
(2, 3, 4) and IRS-2, have a role in GH signaling. Clearly, there is some
overlap in function between IRS-2 and IRS-1. Both IRS-1 and IRS-2 bind
PI 3
-kinase in response to GH (Refs. 3 and 4 and this paper).
Furthermore, 13 of 22 potential tyrosine phosphorylation sites within
IRS-2 are the same as or similar to sites in IRS-1 (5). Signaling
molecules that bind to these shared motifs are likely to be signaling
molecules for both IRS-1 and IRS-2. No downstream signaling molecules
unique to either IRS-1 or IRS-2 have yet been identified. However,
potential for such molecules exists; IRS-2 contains nine potential
phosphorylation sites not shared with IRS-1 and IRS-1 contains five
sites not shared with IRS-2 (5). Distinct roles for IRS-1 and IRS-2 in GH signaling could also arise from differences in tissue expression of
IRS-1 and IRS-2 (5).
We and others have shown that, in addition to GHR, other members of the
cytokine receptor family induce tyrosyl phosphorylation of IRS-2. These
include receptors for LIF and IFN
(this paper); IL-2, IL-4, and IL-7
(10, 28); and IFN
(11). These receptors activate various members of
the JAK kinase family; thus, activation of IRS-2 does not appear to be
limited to a specific JAK. Whether these receptors initiate the same
downstream signaling pathways as the receptors for insulin IGF-1, GH or
each other is not known. However, it seems reasonable to speculate that
different tyrosine kinases will have differing specificities for the 22 tyrosines in IRS-2. In support of this, the receptors for insulin and
IGF-1 have varying specificity for individual tyrosines in IRS-1, at least in vitro (29). Furthermore, in response to GH,
IFN-
, and LIF, there appear to be differences in the extent of
phosphorylation of individual IRS-2 molecules. Thus, different subsets
of signaling molecules might be recruited by IRS-2 in response to
different ligands. Dose and length of exposure to ligand would also
affect the degree of phosphorylation and could therefore potentially affect which signaling molecules are recruited to IRS-2.
The ability of multiple members of the cytokine receptor family to induce tyrosyl phosphorylation of IRS-2 suggests that a region(s) of homology essential for IRS-2 tyrosyl phosphorylation is present in these receptors. Within the cytoplasmic domain of receptors in the cytokine receptor family, two motifs have been recognized, proline-rich box 1 and box 2 (21, 30, 31). These motifs, reported to be required for recognition of the appropriate JAK kinase by these receptors (8, 9, 27, 32, 33, 34, 35, 36, 37), are present in the regions of GHR required for GH-dependent tyrosyl phosphorylation of IRS-2. This suggests that JAK2 may be responsible for phosphorylating IRS-2. The finding that additional regions of GHR do not appear to be required for IRS-2 phosphorylation suggests that IRS-2 may interact directly with JAK2, rather than with GHR. Consistent with the ability of JAK kinases to associate directly with and phosphorylate IRS proteins, when IRS-2 is coexpressed with JAK1 or JAK3 in COS-7 cells, IRS-2 is tyrosyl-phosphorylated and coprecipitates with tyrosyl-phosphorylated JAK1 or JAK3 (10). Furthermore, a complex between IRS-2 and JAK1 has been detected in human T lymphocytes (constitutive) and D10G4.1 T helper lymphocytes (ligand-dependent) (10, 38). A complex between IRS-2 and Tyk2 has been detected in human acute erythroleukemia (HEL) cells (11). Also consistent with a protein other than GHR, such as the Janus kinases, providing a binding site for IRS-2, is the finding that no phosphorylated tyrosines in GHR appear to be required for IRS-2 phosphorylation in response to GH.
The question of whether phosphorylation of IRS-2 requires binding of
IRS-2 to a site within GHR, JAK2, or an accessory protein is an
intriguing one. Phosphorylation of IRS-1 in response to IL-4, insulin,
and IGF-1 appears to require interaction between the phosphotyrosine
binding domain of IRS-1 and a tyrosyl-phosphorylated NPXY
motif in the ligand receptor (22, 23, 25). Since a domain homologous to
the phosphotyrosine binding domain of IRS-1 is present in IRS-2 (5),
IRS-2 has been hypothesized to interact with the NPXY motif
in the receptors for IL-4, insulin, and IGF-1. However, GHR and JAK2 do
not contain NPXY motifs (13, 14). Furthermore, no
phosphorylated tyrosines within GHR appear to be required for
GH-dependent tyrosyl phosphorylation of IRS-2. Thus, as
hypothesized for IRS-1 (3), IRS-2 may primarily interact with an
auxiliary protein in the GHR·JAK2 complex via an NPXpY motif and have only minor, interactions with GHR or JAK2.
Alternatively, there may be several domains in IRS-2 that interact with
ligand-bound receptor complexes. Some of these domains may bind motifs
other than NPXpY and may in fact bind motifs that do not
contain phosphorylated tyrosines. Consistent with IRS-2 associating
with proteins by multiple mechanisms, glutathione
S-transferase fusion proteins containing the pleckstrin
homology domain of IRS-1 or IRS-2 precipitate Tyk2 from extracts of
IFN
-treated human multiple myeloma (U266) cells (11). Consistent
with IRS-2 interacting with an auxiliary protein other than JAK2, in
U266 cells, IFN
stimulates tyrosyl phosphorylation of JAK2 but does
not induce tyrosyl phosphorylation of IRS-2 (11). Perhaps 3T3-F442A
fibroblasts, in which IFN
does induce IRS-2 tyrosyl phosphorylation,
have a signaling molecule that is not present in U266 cells.
The binding of the 85-kDa regulatory subunit of PI 3
-kinase to IRS-2
has been shown to activate PI 3
-kinase (5, 6). Thus, the ability of GH
to recruit p85 to IRS-2 suggests that GH activates PI 3
-kinase.
Potential roles for PI 3
-kinase in GH action include regulation of
glucose transport, nuclear translocation of MAP kinases, and regulation
of protein kinase C. Involvement of PI 3
-kinase in
GH-dependent glucose transport is suggested by the finding
in rat adipocytes that GH-dependent lipid synthesis, which
is metabolically downstream from glucose transport, is blocked by
wortmannin, an inhibitor of PI 3
-kinase (39). GH, like insulin, stimulates glucose transport at least in part by inducing translocation of GLUT4 from low density microsomes to the plasma membrane
(40).4 Wortmannin blocks insulin-stimulated
translocation of GLUT4 glucose transporters from low density microsomes
to the plasma membrane (41).
Involvement of PI 3
-kinase in nuclear translocation of the MAP kinase
ERK1 is suggested by recent studies using wortmannin as well as a
mutant polyomavirus middle-T tumor antigen defective in the ability to
bind PI 3
-kinase (42). ERK1 and ERK2 are activated by GH (43, 44, 45);
therefore, PI 3
-kinase may also be involved in
GH-dependent activation of genes such as c-fos (46, 47, 48) that are thought to require MAP kinase for transcriptional
activation (49, 50, 51).
Phosphatidylinositol 3,4-P2 and phosphatidylinositol
3,4,5-P3, products of PI 3
-kinase, have recently been
shown to activate Ca2+-independent protein kinase C
isoforms
,
, and
(52). The findings that GH induces
translocation of the
isoform of protein kinase C from the cytoplasm
to the plasma membrane in 3T3-F442A fibroblasts (53) and that the PI
3
-kinase inhibitor wortmannin inhibits GH-dependent
diacylglycerol formation in rat adipocytes (54), raise the
possibility that in some cell types, PI 3
-kinase may be involved in
GH-dependent activation of protein kinase C.
The role of SHP2 in GH signaling is presently unknown. It seems
unlikely that SHP2 bound to IRS-2 is the primary phosphatase responsible for dephosphorylating JAK2 and/or GHR. Overexpression of a
catalytically inactive form of SHP2 blocks, rather than stimulates, induction by prolactin of a
-casein reporter gene, a JAK2- and prolactin-dependent event (55). It seems more likely that
functions regulated by SHP2 as a result of GH activation include the
same functions regulated by SHP2 when activated by insulin. SHP2 has been implicated in insulin, IGF-1, and epidermal growth
factor-dependent stimulation of Ras, MAP kinase, DNA
synthesis, and c-fos reporter gene expression (56, 57, 58, 59).
These responses are blocked by overexpression of a catalytically
inactive form of SHP2, suggesting that SHP2 is a positive regulator of
these functions. Presumably some of these or other not yet identified
effects are due to increased phosphatase activity. However, SHP2 has
also been reported to function as an adapter for proteins such as Grb2 (60, 61, 62). Consistent with SHP2 serving as an adapter protein for IRS-1
and IRS-2, in baby hamster kidney cells stably expressing insulin
receptor and transiently overexpressing IRS-1, overexpression of SHP2
increases the amount of IRS-1 associated with insulin receptor (63). In
addition, overexpression of SHP2 (either wild-type or catalytically
inactive) increases insulin-dependent glucose transport in
cells transiently overexpressing IRS-1 (63). Since the MAP kinase
cascade, c-fos gene expression, and glucose transport are
also regulated by GH, it seems likely that the SHP2 which binds to
IRS-2 in response to GH may play a role in the regulation of these
functions by GH.
These results showing that GH promotes tyrosyl phosphorylation of
IRS-2 and association of SHP2 and the 85-kDa regulatory subunit of PI
3
-kinase with IRS-2 provide evidence that IRS-2 has a role in GH
signaling. GH-dependent association of SHP2 with IRS-2
identifies a potential mechanism for GH-dependent
activation of this phosphatase. The finding that the region of GHR
required for IRS-2 tyrosyl phosphorylation is the same region required for JAK2 association and activation, and that phosphotyrosines in GHR
do not appear to be required for GH-dependent tyrosyl
phosphorylation of IRS-2, suggests that interaction of IRS-2 with the
GHR-JAK2 complex may occur principally through JAK2 or an auxiliary
molecule associated with JAK2. The abilities of LIF and IFN
to also
stimulate tyrosyl phosphorylation of IRS-2 suggest that signaling
through IRS-2 may be common to many members of the cytokine receptor
family. However, differences in duration and magnitude of IRS-2 tyrosyl phosphorylation in response to GH, LIF, IFN
, and insulin suggest that the ultimate biologic responses culminating from signaling through
IRS-2 could differ for the different ligands.

To whom correspondence should be addressed. Fax: 313-936-8813;
cartersu{at}umich.edu.
, interferon-
; IL, interleukin;
LIF, leukemia inhibitory factor; PI 3
-kinase, phosphatidylinositol
3
-kinase; SHP2, Src homology 2 domain-containing protein-tyrosine
phosphatase 2; MAP, mitogen-activated protein.
We thank Pinyi Du for technical assistance.
This article has been cited by other articles:
![]() |
H. Jin, N. J. Lanning, and C. Carter-Su JAK2, But Not Src Family Kinases, Is Required for STAT, ERK, and Akt Signaling in Response to Growth Hormone in Preadipocytes and Hepatoma Cells Mol. Endocrinol., August 1, 2008; 22(8): 1825 - 1841. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hashita, T. Sakuma, M. Akada, A. Nakajima, H. Yamahara, S. Ito, H. Takesako, and N. Nemoto Forkhead Box A2-Mediated Regulation of Female-Predominant Expression of the Mouse Cyp2b9 Gene Drug Metab. Dispos., June 1, 2008; 36(6): 1080 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, Z. Li, D. L. Morris, and L. Rui Identification of SH2B2{beta} as an Inhibitor for SH2B1- and SH2B2{alpha}-Promoted Janus Kinase-2 Activation and Insulin Signaling Endocrinology, April 1, 2007; 148(4): 1615 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. KOKK, E. VERAJANKORVA, X.-K. WU, H. TAPFER, E. POLDOJA, H.-E. SIMOVART, and P. POLLANEN Expression of Insulin Signaling Transmitters and Glucose Transporters at the Protein Level in the Rat Testis Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 262 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |